drugset

drugset / Trial / NCT05682222

Evaluation of the Immunopharmacology of EDP1815 and EDP2939

NCT05682222 ↗

Phase 1 Completed 38 enrolled Evelo Biosciences, Inc.

RandomizedSequentialDouble-blindTreatment

Summary

A single-center, randomized, double-blind, placebo-controlled, multiple dose platform trial.

Timeline

Start: 2022-06-27
Primary completion: 2022-10-14
Completion: 2022-10-14

Publications

Eveleens Maarse BC, Ronner MN, Jansen MAA, Niemeyer-van der Kolk T, In 't Veld AE, Klaassen ES, Ahmad S, Itano A, McHale D, Moerland M. Immunomodulating effects of the single bacterial strain therapy EDP1815 on innate and adaptive immune challenge responses - a randomized, placebo-controlled clinical trial. Immunol Res. 2024 Aug;72(4):776-787. doi: 10.1007/s12026-024-09484-7. Epub 2024 May 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EDP1815	Other / unclassified	8e+10 cells	Oral
Subject	EDP2939	Other / unclassified	—	Oral

Indications

No indication recorded.